Herzog TJ - Search Results

1

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Monk BJ, et al. Among authors: herzog tj. J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516432 Clinical Trial.

2

Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE; Gynecologic Oncology Group. Moore DH, et al. Among authors: herzog tj. J Clin Oncol. 2003 Nov 15;21(22):4207-13. doi: 10.1200/JCO.2003.02.086. J Clin Oncol. 2003. PMID: 14615449 Clinical Trial.

3

Recurrent ovarian cancer: how important is it to treat to disease progression?

Herzog TJ. Herzog TJ. Clin Cancer Res. 2004 Nov 15;10(22):7439-49. doi: 10.1158/1078-0432.CCR-04-0683. Clin Cancer Res. 2004. PMID: 15569973 Review.

4

Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.

Lewin SN, Mutch DG, Whitcomb BP, Liapis H, Herzog TJ. Lewin SN, et al. Among authors: herzog tj. Gynecol Oncol. 2005 Apr;97(1):228-33. doi: 10.1016/j.ygyno.2004.12.027. Gynecol Oncol. 2005. PMID: 15790464

5

CA-125 response in patients with recurrent ovarian or primary peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan.

Gossner G, Coleman RL, Mutch DG, Horowitz NS, Rader JS, Gibb RK, Powell MA, Herzog TJ. Gossner G, et al. Among authors: herzog tj. Gynecol Oncol. 2006 Oct;103(1):212-8. doi: 10.1016/j.ygyno.2006.02.026. Epub 2006 May 3. Gynecol Oncol. 2006. PMID: 16677696

6

Phase II evaluation of a 3-day infusion of topotecan in patients with recurrent ovarian or primary peritoneal cancer.

Herzog TJ, Powell MA, Rader JS, Gibb R, Mutch DG. Herzog TJ, et al. Gynecol Oncol. 2006 Nov;103(2):637-41. doi: 10.1016/j.ygyno.2006.04.014. Epub 2006 Jun 15. Gynecol Oncol. 2006. PMID: 16781766 Clinical Trial.

7

The current treatment of recurrent ovarian cancer.

Herzog TJ. Herzog TJ. Curr Oncol Rep. 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. Curr Oncol Rep. 2006. PMID: 17040623 Review.

8

Ovarian cancer: a focus on management of recurrent disease.

Herzog TJ, Pothuri B. Herzog TJ, et al. Nat Clin Pract Oncol. 2006 Nov;3(11):604-11. doi: 10.1038/ncponc0637. Nat Clin Pract Oncol. 2006. PMID: 17080178 Review.

9

The evolution of cost-effective screening and prevention of cervical carcinoma: implications of the 2006 consensus guidelines and human papillomavirus vaccination.

Monk BJ, Herzog TJ. Monk BJ, et al. Among authors: herzog tj. Am J Obstet Gynecol. 2007 Oct;197(4):337-9. doi: 10.1016/j.ajog.2007.08.030. Am J Obstet Gynecol. 2007. PMID: 17904955 No abstract available.

10

Reducing the burden of glandular carcinomas of the uterine cervix.

Herzog TJ, Monk BJ. Herzog TJ, et al. Am J Obstet Gynecol. 2007 Dec;197(6):566-71. doi: 10.1016/j.ajog.2007.08.055. Am J Obstet Gynecol. 2007. PMID: 18060938

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

404 results

Search Page

Filters